Results 61 to 70 of about 266,924 (341)

Cell density–dependent nuclear‐cytoplasmic shuttling of SETDB1 integrates with Hippo signaling to regulate YAP1‐mediated transcription

open access: yesFEBS Letters, EarlyView.
At low cell density, SETDB1 and YAP1 accumulate in the nucleus. As cell density increases, the Hippo pathway is gradually activated, and SETDB1 is associated with increased YAP1 phosphorylation. At high cell density, phosphorylated YAP1 is sequestered in the cytoplasm, while SETDB1 becomes polyubiquitinated and degraded by the ubiquitin–proteasome ...
Jaemin Eom   +3 more
wiley   +1 more source

Determinants of Growth, Adiposity and Bone Mass in Early Life [PDF]

open access: yes, 2016
Environmental influences during fetal life and early infancy have been suggested to influence body composition throughout the life-course. Especially poor fetal nutrition and fetal growth restriction have been designated important risk factors for ...
Heppe, D.H.M. (Denise)
core  

Cardiovascular Programming During and After Diabetic Pregnancy: Role of Placental Dysfunction and IUGR [PDF]

open access: yes, 2019
Intrauterine growth restriction (IUGR) is a condition whereby a fetus is unable to achieve its genetically determined potential size. IUGR is a global health challenge due to high mortality and morbidity amongst affected neonates.
Dechend, Ralf   +6 more
core   +2 more sources

Early onset fetal growth restriction [PDF]

open access: yesBest Practice & Research Clinical Obstetrics & Gynaecology, 2017
Fetal growth restriction remains a challenging entity with significant variations in clinical practice around the world. The different etiopathogenesis of early and late fetal growth restriction with their distinct progression of fetal severity and outcomes, compounded by doctors and patient anxiety adds to the quandary involving its management.
Aamod Nawathe, Christoph Lees
openaire   +4 more sources

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

open access: yesMolecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou   +5 more
wiley   +1 more source

Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction

open access: yesScientific Reports, 2022
Fetal growth restriction (FGR) and pre-eclampsia with fetal growth restriction (PE/FGR) are high-risk perinatal diseases that may involve high levels of human chorionic gonadotropin (hCG) and mitochondrial dysfunction.
Ryo Kiyokoba   +7 more
doaj   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Umbillical venous volume inflow and liver size in normal and abnormal fetal development [PDF]

open access: yes, 2003
In this thesis the following research objectives were addressed: To calculate umbilical venous volume flow from cross-sectional area and flow velocity measurements with emphasis on: (i) the reproducibility of component measurements; (ii) normal and ...
Boito, S.M.
core  

The impact of a human IGF-II analog ([Leu27]IGF-II) on fetal growth in a mouse model of fetal growth restriction. [PDF]

open access: yes, 2016
Enhancing placental insulin-like growth factor (IGF) availability appears to be an attractive strategy for improving outcomes in fetal growth restriction (FGR).
Aplin, JD   +5 more
core   +2 more sources

Home - About - Disclaimer - Privacy